Summary: Cerebral ammonia metabolism was studied in five control subjects and five patients with severe liver disease exhibiting minimal hepatic encephalopathy. The arterial ammonia concentration in the control subjects was 30 ± 7 /l-mollL (mean ± SD) and 55 ± 13 /l-mollL in the patients (p < 0.01). In the normal subjects. the whole brain values for cerebral blood flow. cerebral metabolic rate for ammonia. and the permeability-surface area product for ammonia were 0.58 ± 0.12 ml g-I min-I, 0.35 ± 0. 15 /l-mol 100 g--I min-I, and 0.13 ± 0.03 ml g-I min -I. respectively. In the patients, the respective val ues were 0.46 ± 0. 16 ml g -I min -I (not different from control), 0.91 ± 0.36 /l-mol 100 g-I min -I (p < 0.025), Abbreviations used: aPS, apparent permeability-surface area product; PET, positron emission tomography; rCMRA, regional cerebral metabolic rate of ammonia.
337and 0.22 ± 0.07 ml g -I min -I (p < 0.05). The increased permeability-surface area product of the blood-brain bar rier permits ammonia to diffuse across the blood-brain barrier into the brain more freely than normal. This may cause ammonia-induced encephalopathy even though ar terial ammonia levels are normal or near normal and ex plain the emergence of toxin hypersensiti vity as liver dis ease progresses. Greater emphasis on early detection of encephalopathy and aggressive treatment of minimal hy perammonemia may retard the development of ammonia induced complications of severe liver disease. Key Words: Hepatic encephalopathy-Ammonia-Blood brain barrier-Positron emission tomography. lock, 1958). This has raised doubt about the impor tance of ammonia in coma production.We have used positron emission tomography (PET) to investigate cerebral ammonia metabolism in patients with severe liver disease and in a group of normal controls. We report a significant increase in the cerebral metabolic rate for ammonia in the patients with liver disease that is associated with an increase in the cerebral extraction of ammonia and an increase in the apparent permeability-surface area (aPS) product. The resulting increase in the ease with which ammonia moves into the brain from the blood may account for the development of toxin hypersensitivity and explain the presence of cere bral dysfunction in patients with near-normal arte rial ammonia concentrations. A preliminary report of this work has been presented in abstract form (Lockwood and Yap, 1989).
METHODS
Patient selectionPatients and controls were enrolled in this study using informed consent guidelines and protocols approved by the University of Texas Health Science Center at Hous-